Lucence

United States · Research

Lucence is a precision oncology company founded in 2016 and based in Singapore, with operations in California. The company specializes in developing advanced liquid biopsy blood tests aimed at earlier cancer detection and improved treatment selection. Their technology allows for non-invasive cancer diagnostics by analyzing blood samples to create molecular profiles of tumors, enabling physicians to make informed treatment decisions without the need for invasive tissue biopsies. Lucence offers clinical services to cancer physicians and oncologists, providing detailed molecular profiles from blood samples to support treatment decisions. Their product portfolio includes somatic cancer tests like LiquidHallmark, which utilize next-generation sequencing and PCR technologies to detect various cancer types, including nasopharyngeal cancer and hematological malignancies. The company focuses on enhancing test sensitivity to detect a wider range of cancers at earlier stages, ultimately improving patient outcomes. Lucence collaborates with organizations like Mayo Clinic Laboratories and utilizes global logistics partnerships to ensure efficient distribution of testing services.